Portal hypertension can begin in the early, compensated stage of cirrhosis, but it becomes clinically significant and dangerous as the disease progresses toward decompensation. The key threshold is a pressure gradient of 10 mmHg or higher between the portal vein and the hepatic veins. Below that, portal hypertension may exist but typically causes no symptoms. At 10 mmHg and above, the risk of serious complications like fluid buildup, bleeding, and confusion begins to climb.
How Pressure Builds Through Cirrhosis Stages
In a healthy liver, the pressure difference between the portal vein (which carries blood from the gut to the liver) and the veins draining the liver stays at 5 mmHg or less. As cirrhosis develops and scar tissue distorts the liver’s internal architecture, blood flow meets increasing resistance. A gradient of 6 mmHg or higher technically qualifies as portal hypertension, but a reading between 5 and 9 mmHg is considered subclinical. Most people in this range have no symptoms and may not know anything is wrong.
The critical shift happens at 10 mmHg. This is the threshold for clinically significant portal hypertension, and it marks the point where the body can no longer compensate. Enlarged veins (varices) start forming in the esophagus and stomach as blood seeks alternate routes around the blocked liver. At 12 mmHg and above, those varices can rupture and bleed, fluid can accumulate in the abdomen (ascites), and toxins the liver normally clears can build up in the brain, causing confusion and disorientation known as hepatic encephalopathy. These events collectively define decompensated cirrhosis.
Compensated vs. Decompensated Cirrhosis
Cirrhosis is broadly divided into two phases. In the compensated phase, the liver is scarred but still functional enough to avoid major complications. Portal pressure may already be elevated, but the body manages. Patients in this phase can live for years. One study of patients with mild portal hypertension found a median survival of 11 years, though their survival was still lower than the general population.
Decompensated cirrhosis begins the moment a patient develops their first major complication: ascites, variceal bleeding, or encephalopathy. About 30% of patients with acute decompensation go on to develop failure in organs beyond the liver. The transition from compensated to decompensated is not always gradual. Some patients remain stable for years before a sudden bleed or rapid fluid accumulation signals that portal pressure has crossed a dangerous line.
How Portal Hypertension Is Detected
Doctors often suspect portal hypertension based on visible signs rather than direct pressure measurement. An enlarged spleen, low platelet count, fluid in the abdomen, or dilated veins on the abdominal wall all point toward elevated portal pressure. Doppler ultrasound can show blood flow patterns in the portal vein system, revealing blockages or abnormal vessel widening. If there are signs of gastrointestinal bleeding, an upper endoscopy allows doctors to look directly at the esophagus and stomach for swollen varices.
Direct pressure measurement requires a specialized catheter procedure that isn’t performed routinely. Instead, recent international guidelines (the Baveno VII consensus) now support using non-invasive methods to estimate whether portal hypertension has reached clinically significant levels. A liver stiffness measurement of 25 kPa or higher on ultrasound-based elastography, combined with platelet count, can reliably identify patients with significant portal hypertension without an invasive procedure. Conversely, a stiffness reading of 15 kPa or less with platelets above 150,000 effectively rules it out.
Varices and Bleeding Risk
Esophageal varices are present in roughly half of all people with cirrhosis. These are swollen veins that form when portal blood pressure forces blood into smaller vessels in the esophagus and stomach lining, vessels never designed to handle that volume. Varices themselves don’t cause symptoms until they bleed, which is why screening endoscopy matters.
The risk of bleeding correlates with how advanced the liver disease is. In one study of patients with variceal bleeding, only 2% had the mildest form of cirrhosis (Child-Pugh A), while 40% had moderate disease (Child-Pugh B) and 52% had severe disease (Child-Pugh C). Among patients with cirrhosis who had never bled, the pattern was reversed: 64% were in the mildest category. This makes clear that variceal bleeding is overwhelmingly a problem of advanced, decompensated disease.
How Severity Is Scored
The Child-Pugh classification grades cirrhosis severity on a point system using five factors: the presence and severity of encephalopathy, the amount of ascites, and three blood test results (bilirubin, albumin, and clotting time). Each factor scores 1 to 3 points. A total of 5 to 6 points is Class A (mild, generally compensated), 7 to 9 is Class B (moderate), and 10 to 15 is Class C (severe). Portal hypertension complications like ascites and encephalopathy directly push patients into higher classes.
The MELD-Na score, which is used to prioritize patients for liver transplant, relies on different lab values and does not directly account for portal hypertension. This can be a problem. Patients with fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease) tend to develop serious variceal bleeding at lower MELD-Na scores than patients with alcohol-related or viral liver disease. Their scores may look deceptively modest even when portal hypertension complications are life-threatening, potentially delaying transplant prioritization.
Managing Portal Pressure
Once clinically significant portal hypertension is identified, treatment focuses on preventing the first bleed or stopping recurrent ones. Blood pressure medications called non-selective beta-blockers are the standard approach. These drugs reduce the heart rate and constrict blood vessels feeding the portal system, lowering the pressure inside varices. The goal is typically a resting heart rate between 55 and 60 beats per minute while keeping systolic blood pressure above 90 mmHg.
The maximum doses of these medications are cut roughly in half for patients who already have ascites, because their cardiovascular system is more fragile. Treatment is lifelong once started. If beta-blockers aren’t tolerated or aren’t enough, doctors may place small rubber bands around varices during endoscopy to cut off blood flow to them, a procedure called band ligation. For patients with severe or recurrent bleeding, a procedure that creates a new pathway for blood to bypass the liver (called a TIPS) may be considered, though this carries its own risks, including worsening encephalopathy.
Addressing the underlying cause of cirrhosis remains the most effective way to slow or partially reverse portal hypertension. Eliminating alcohol, treating hepatitis B or C, or managing metabolic liver disease can reduce liver inflammation and, in some cases, allow scar tissue to partially remodel. When portal pressure drops below 10 mmHg with treatment, the risk of decompensation drops substantially.